Lexology April 15, 2022
Hogan Lovells

On April 14, the U.S. Food and Drug Administration (FDA) released a new draft guidance to industry for increasing racial and ethnic diversity in clinical trials. The draft guidance, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials,” recommends that sponsors develop and submit a Race and Ethnicity Diversity Plan (referred to as the “Plan”) to FDA before beginning clinical trials, based on a framework outlined in the guidance, noting that consideration of demographic factors like race and ethnicity are critical to the generalizability of study results.

FDA recommends the submission of a Plan for all medical products for which an IND submission is required or for which clinical studies are intended to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Trends
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
FDA approves Akebia anemia pill, two years after rejection
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
FDA approves Merck drug for rare lung disorder
Neuronetics wins FDA clearance for device to treat adolescents with depression

Share This Article